This report on the global prostate cancer treatment market examines various drugs used to treat prostate cancer, as well as a pipeline analysis of potential new drugs. According to the National Cancer Institute, approximately 12.9% of men will be diagnosed with prostate cancer at some point during their lifetime. Prostate cancer can be diagnosed before the symptoms start by testing the prostate-specific antigen (PSA) in a man’s blood or through the digital rectal exam (DRE). Currently, there are a handful of players that are leading the prostate cancer treatment market, but in the future, the competition will be more intense as several blockbuster prostate cancer therapeutic drugs are slated to go off-patent.
For the purpose of this study, the various treatment types studied include biological therapy, which includes drugs like Enzalutamide (Xtandi), Abiraterone (Zytiga), and chemotherapy drugs like Docetaxel (Taxotere), and Cabazitaxel (Jevtana). Market size estimates and forecasts for these segments for the period 2015 to 2025 are provided in terms of US$ Mn, along with the respective CAGRs for the period 2017 to 2025, considering 2016 as the base year.
The pipeline analysis for the prostate cancer treatment market includes estimated market sales of Phase III drugs through 2025. We have estimated sales of very specific molecules based on the type (biological or chemical), sponsor, depicted peak sales by leading market experts, and other factors. A few prominent phase III drugs are ProstVac, Tasquinimod Active, ARN-509, ODM-201, and Yervoy, etc.
The geographic segmentation of the global prostate cancer treatment market is performed for the regions of North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. The regions are also further sub-segmented on the basis of major countries. Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.
The American Cancer Society (ACS) estimates that more than 12 million new cases of cancer are diagnosed worldwide each year. Around 99% of the cases of prostate cancer are most commonly seen after the age of 50ncer are diagnosed worldwide each year. Around 99% of the cases of prostate cancer are most commonly seen after the age of 50. Based on the treatment type, the prostate cancer treatment market is segmented into:
- Mitotic inhibitors, e.g., Docetaxel, Cabazitaxel
- Topoisomerase inhibitors, e.g., mitoxantrone
- alkylating antineoplastic agent, e.g., estramustine
According to market experts, biological therapy is the first line of treatment in order to reduce androgens in the body (testosterone and dihydrotestosterone) as they stimulate the growth of prostate cancer cells. However, the drug-related side effects are high, so patients are opting for chemotherapy, where drugs such as docetaxel, cabazitaxel, mitoxantrone, and estramustine are prescribed for the treatment of prostate cancer. Chemotherapy is a treatment of choice for patients who have become resistant to biological therapy and whose prostate cancer has spread outside the prostate gland and metastasized in distant organs. Biological therapy had the largest market share in the treatment in 2016, followed by chemotherapy. Targeted biological therapy is expected to grow significantly between 2017 and 2025, owing to a promising pipeline. Improved reimbursement policies, which have increased treatment expenditure in developed markets; an aging population coupled with growing public awareness; and technological advancements in drug development with promising pipeline products for the treatment of prostate cancer were the key factors assisting segment growth.
Or, for the purpose of this study, the global prostate cancer treatment market is categorized into:
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
In 2016, North America was identified as the largest market for prostate cancer treatment. According to the American Cancer Society, in 2017, there will be about 161,360 new cases of prostate cancer, attributed mainly to an aging population and high public awareness of the disease, which has led to early diagnosis and treatment for prostate cancer. Cancer Research UK states that prostate cancer accounts for 26% of all new cases of cancer in males. Europe is expected to be the second-largest market due to rising public awareness related to early disease diagnosis, improved healthcare infrastructure, government and non-government organizations arranging awareness activities and camps, and supportive reimbursement policies. Newly approved drug molecules for the treatment of pancreatic cancer have a good acceptance and penetration rate in the European market. The growth of the Asia Pacific prostate cancer treatment market is attributed to factors like the rising prevalence of the disease, increasing investments in R&D, and higher disposable income in these regions. However, factors such as developing health infrastructure, increasing awareness among people about health care, and an aging population are going to fuel the rapid growth of the prostate cancer treatment market in Latin America, the Middle East, and Africa in the near future.